STOCK TITAN
  1. Home
  2. Sec-filings
  3. XFOR
  4. [SCHEDULE 13G/A] X4 Pharmaceuticals, Inc. SEC Filing

[SCHEDULE 13G/A] X4 Pharmaceuticals, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock XFOR logo
X4 Pharmaceuticals Inc

NASDAQ:XFOR

XFOR Rankings

#5462 Ranked by Market Cap
N/A Ranked by Dividends

XFOR Latest News

Aug 15, 2025
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 13, 2025
X4 Pharmaceuticals Announces Closing of Upsized $85 Million Private Placement
Aug 12, 2025
X4 Pharmaceuticals Announces $60 Million Equity Financing with Concurrent Changes in Management and Board Leadership
Jun 16, 2025
X4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA)
Jun 10, 2025
X4 Pharmaceuticals Granted Fast Track Designation for Mavorixafor for the Treatment of Chronic Neutropenia by U.S. FDA

XFOR Latest SEC Filings

Aug 15, 2025
[SCHEDULE 13D/A] X4 Pharmaceuticals, Inc. SEC Filing
Aug 14, 2025
[Form 4] X4 Pharmaceuticals, Inc. Insider Trading Activity
Aug 14, 2025
[Form 3] X4 Pharmaceuticals, Inc. Initial Statement of Beneficial Ownership
Aug 14, 2025
[Form 3] X4 Pharmaceuticals, Inc. Initial Statement of Beneficial Ownership
Aug 14, 2025
[Form 4] X4 Pharmaceuticals, Inc. Insider Trading Activity

XFOR Stock Data

33.43M
5.47M
2.49%
57.89%
5.44%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
BOSTON